Advertisement

Topics

I-131 Mini Caps Medical Professional Information Sheet | I 131 Mini [AnazaoHealth Corporation] | BioPortfolio

13:22 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Dear Medical Professional, Per your order, we have compounded I-131 in Mini Cap form. The characteristics of this compound are:

Sodium Iodide I-131 (NaI-131) for therapeutic use is supplied for oral administration in small opaque white gelatin capsules, inside a blue and clear outer capsule. Each I-131 mini capsule is available in strengths ranging from (0.1 – 150 mCi) at the time of calibration. Iodine 131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days.

Sodium Iodide I-131 Mini Capsules are compounded by absorbing a solution of carrier-free sodium iodide I-131 into inert filler. The iodine 131 utilized in the preparation of the capsules contains not less than 99% Iodine-131 at the time of calibration.

Gelatin capsules are compounded per prescription requirements using high specific concentration I-131, allowing higher iodine activity in a small easy to swallow high activity capsule size.  Capsules are formulated to rapidly dissolve in saline solution, to allow use for oral solution administration when clinically necessary.

Radioiodine is excreted in human milk during lactation; breast feeding must be substituted during and following dose administration. Sodium Iodide 131 is not usually used for treatment of hyperthyroidism in patients under 30 years of age.  Reactions to administration are rare; however potential side effects such as radiation sickness and bone marrow depression, acute leukemia, anemia, chromosomal abnormalities, acute thyroid crisis, blood dyscrasia, leukopenia, thrombocytopenia, and death represent potential side effects.

Anti-thyroid therapy of a severely hyperthyroid patient is usually discontinued three to four days before administration of radioiodide.  For hyperthyroidism, the usual dose range is 4 to 10 mCi.  Toxic nodular goiter and other special situations will require the use of larger doses.  For thyroid carcinoma, 50 mCi is the usual dose for ablation of normal thyroid tissue, and 100 to 150 mCi is the usual subsequent therapeutic dose. Waterproof gloves should be used during the entire handling and administration procedure. Adequate shielding must be maintained.

Most patients with thyroid disease present with a thyroid nodule. Tools utilized to assess thyroid nodules and to rule out thyroid cancer include: serum thyroid function tests (TSH and thyroid hormone level), thyroid ultrasound (US), radionuclide scintigraphy (low activity I-131, I-123 and/or Tc99m), and fine needle aspiration (FNA) for cytology (cells) examination.  High thyroid hormone levels (T4 or T3) and a low TSH level may indicate a nodule is a benign hyperfunctioning nodule (adenoma), thereby tending to rule out thyroid cancer.  In such cases, thyroid imaging (US or scintigraphy) determines whether the nodule is hyperfunctioning whereas thyroid cancers appear under-functioning or “cold” on the scan. Graves’ disease and Hashimotos’ thyroiditis represent thyroid diseases which occur in children who have autoimmune thyroid disease. In these patients, abnormal thyroid function tests reflect underlying thyroid disease but do not exclude thyroid cancer.

The administration of radioiodine has proved to be an excellent method of destruction of over functioning thyroid tissue (either diffuse or toxic nodular goiter). Radioiodine is concentrated in the thyroid, destroying cells that concentrate it.

Surgical removal is the treatment of choice for thyroid carcinomas. At 2 to 4 months post surgery, a whole-body I-131 scan is performed following cessation of thyroxin drug for 4-6 weeks prior to the scan, thereby causing hypothyroidism; TSH then rises and stimulates iodide uptake.  Iodine-containing foods and contrast media are avoided. Patients with significant I-131 uptake are given ablative (100 - 150 mCi) doses of I-131. For minimal uptake, doses of 30-50 mCi I-131 are given on an outpatient basis.  Patients with extra thyroidal uptake from metastatic disease may be given larger doses of greater than 100 mCi.

I-131 THERAPY CAPSULE MARKET BACKGROUND

I-131 Therapy Capsule formulations provide an enhanced safety profile for nuclear medicine professionals. Oral solutions raise the risk for spills during administration in addition to the not uncommon scenario where very ill patients reject oral solution treatment; whereupon vomiting episodes create large areas of high level radiation spill. Oral solutions, however, are sold at deep discounts as compared to Therapy Capsules.

While many U.S. facilities have moved to adopt ALARA recommendations to reduce radiation exposure to healthcare workers which reasonably include routinely ordering encapsulated high activity I-131; the scenario also exists that the intended patient may not be able to swallow the Therapy Capsule for reasons including: the large size of competitive suppliers, as well as intubated, quadriplegia and/or severe swallowing difficulties. In these instances, it is particularly beneficial to have the ability to dissolve the capsule so that the patient may be treated on the same day, without having to order additional preparation.

Thank you,

AnazaoHealth Corporation

Manufacturer

AnazaoHealth Corporation

Active Ingredients

Source

Drugs and Medications [21 Associated Drugs and Medications listed on BioPortfolio]

Sodium chloride [baxter healthcare corporation]

0.09% Sodium chloride IN WATER FOR INJECTION

Prenate mini [avion pharmaceuticals, llc]

Prenate Mini 75854-0315-30

Sodium chloride [baxter healthcare corporation]

0.9 % Sodium Chloride Injection, USP

I 123 mini [anazaohealth corporation]

I-123 Mini Caps Medical Professional Information Sheet

Dextrose [baxter healthcare corporation]

5% Dextrose Injection, USP In MINI-BAG Plus Container

Clinical Trials [344 Associated Clinical Trials listed on BioPortfolio]

Mini-laparotomy Versus Mini Lumbotomy

This study aims to compare the results of two mini invasive surgical approaches in abdominal aortic surgery: mini lumbotomy with retroperitoneal approach versus mini laparotomy with transp...

Evaluation of Four Surgical Techniques in Primary Total Hip Arthroplasty

Current "Minimally Invasive THR" includes: (1) Minimally Invasive Two-Incision THR (MIS-2), (2) Minimally Invasive Modified Watson-Jones THR (MIS-WJ). In contrast, "mini-incision" utilizes...

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

The primary aims of this study are to assess: 1. The inter-rater and test-retest reliability of the MINI-KID 2. The validity of the standard MINI-KID interview in relation to the par...

Standard-PCNL vs Mini-PCNL vs Super-mini PCNL for the Treatment of ≥2 cm Renal Stone

Background: Standard-PCNL was considered as the first choice for ≥2 cm renal stones. Miniaturized technique Mini-PCNL has also been implicated in the past two decades. Recently, Super-mi...

Reliability and Validity of the ACTIVE-mini for Quantifying Movement in Infants With Spinal Muscular Atrophy

The purpose of this study is to investigate the measurement properties of the Ability Captured Through Interactive Video Evaluation-mini (ACTIVE-mini) for quantifying movement in infants w...

PubMed Articles [370 Associated PubMed Articles listed on BioPortfolio]

Right Mini-thoracotomy Bentall Procedure.

Bentall procedures are traditionally performed through a median sternotomy. The right mini-thoracotomy approach is increasingly used in aortic valve replacement. This approach has been shown to have d...

Ambulatory Tubeless Mini-PCNL using Moses Technology and Dusting Technique.

To demonstrate the use of the Moses technology for holmium laser lithotripsy in conjunction with mini-PCNL to treat a lower pole stone. The Moses technology is a pulse modulation method that can reduc...

Mini-Sling Ophira at 8 Years Follow-Up: Does It Sustain Results?

To evaluate mini-sling long-term results and correlate them to failure predictors. Many studies show comparable results among different single-incision slings developed as an attempt to reduce complic...

Palmitate enhanced the cytotoxicity of ZnO nanomaterials possibly by promoting endoplasmic reticulum stress.

We recently synthesized ZnO nanomaterials (denoted as ZnO nanorods [NRs] and Mini-NRs) and suggested that their cytotoxicity could be related with the activation of endoplasmic reticulum (ER) stress a...

Mini photopheresis for refractory chronic graft-versus-host disease in children and adolescents.

Extracorporeal photopheresis (ECP) has been established to treat graft-versus-host disease. Our mini ECP technique (mini-ECP) allows for treatment of patients with GVHD and contraindications for class...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record